Blood Advances, a Journal of the American Society of Hematology, provides an open international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology and related sciences. Music for Blood Advances Talks is preformed by the Art Topilow Trio
…
continue reading
![Artwork](/static/images/128pixel.png)
1
GRNDaD: big data and sickle cell disease
15:45
15:45
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
15:45
Big data are used in the pursuit of precision medicine in the general population. Applying these tools to patients with sickle cell disease (SCD) is essential for ensuring that they receive the most appropriate customized therapy for their disease. For these tools to be applied, there must be a large number of willing, fully phenotyped participants…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Investigational curative gene therapy approaches to sickle cell disease
12:58
12:58
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
12:58
Sickle cell disease (SCD) is an inherited blood condition resulting from abnormal hemoglobin production. It is one of the most common genetic diseases in the world. The clinical manifestations are variable and range from recurrent acute and debilitating painful crises to life-threatening pulmonary, cardiovascular, renal, and neurologic complication…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Why is AAV FVIII gene therapy not approved by the US Food and Drug Administration yet?
31:22
31:22
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
31:22
The prospect of a clinical strategy using an adeno-associated virus (AAV) vector for expression of therapeutic levels of factor VIII (FVIII) has been highly desirable. This was initially anticipated by promising data from clinical studies on AAV5-FVIII in men with severe hemophilia A. However, long-term follow-up showed a unique efficacy concern on…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
17:50
17:50
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
17:50
The availability of novel nonfactor therapeutics is revolutionizing the management of hemophilia in individuals with inhibitory antibodies, as well as making prophylaxis more convenient even in the absence of inhibitors. Unfortunately, the use of these products has been associated with thrombotic events that are not typically seen with factor repla…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Concizumab: a novel anti-TFPI therapeutic for hemophilia
15:48
15:48
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
15:48
Amy Shapiro discusses the recent approval of concizumab for the treatment of patients with hemophilia. This novel subcutaneous homeostatic rebalancing agent has proven to be useful for the treatment of patients with hemophilia A and B, and we hope you find this talk to be useful to understand it.Blood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Naive T-cell depletion in stem cell transplantation
24:05
24:05
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
24:05
Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but can also cause graft-versus-host disease (GVHD), with significant morbidity and mortality.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The management of venous thromboembolism in hospitalized patients with COVID-19
15:10
15:10
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
15:10
The high incidence of thromboembolic disease, and in particular venous thromboembolism (VTE), has emerged as an important consideration in hospitalized and critically ill patients with coronavirus disease 2019 (COVID-19).Blood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Gene therapy for hemophilia: anticipating the unexpected
16:35
16:35
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
16:35
The treatment of hemophilia, which has undergone many transformative changes over the past 60 years, is poised for yet another disruptive change: the use of gene therapy to produce functional cures in some persons with hemophilia A or B.Blood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The changing landscape of anticoagulation in cancer-associated thrombosis
16:26
16:26
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
16:26
The changing landscape of anticoagulation in cancer-associated thrombosisBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
TA-TMA: state of the art for diagnosis and treatment
19:30
19:30
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
19:30
Blood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Inherited predisposition to myeloid malignancies
18:39
18:39
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
18:39
Inherited predisposition to myeloid malignancies by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure
21:36
21:36
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
21:36
Managing patients who are receiving warfarin (or DOAC)and need an elective surgery or procedure by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Daily light-and-darkness onset regulates mouse hematopoietic stem cells
17:14
17:14
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
17:14
Daily light-and-darkness onset regulates mouse hematopoietic stem cells by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Extended therapy for unprovoked venous thromboembolism: when is it indicated?
16:16
16:16
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
16:16
Extended therapy for unprovoked venous thromboembolism: when is it indicated? by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances
16:21
16:21
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
16:21
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
Challenges facing the benign hematology physician-scientist workforce by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Choosing for whom to recommend allogeneic transplantation for AML in CRL
17:58
17:58
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
17:58
Choosing for whom to recommend allogeneic transplantation for AML in CRL by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Catalyzing innovation in clinical trial design and analysis at NHLBI
15:25
15:25
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
15:25
Catalyzing innovation in clinical trial design and analysis at NHLBI by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ITP and thrombosis: an intriguing association
23:51
23:51
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
23:51
ITP and thrombosis: an intriguing association by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The current therapeutic landscape of FLT3 inhibitors
15:31
15:31
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
15:31
The current therapeutic landscape of FLT3 inhibitors by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How many mice? Design considerations for murine studies
16:22
16:22
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
16:22
How many mice? Design considerations for murine studies by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Direct Oral Anticoagulants – can we finally stop using rat poison?
10:02
10:02
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
10:02
The Direct Oral Anticoagulants – can we finally stop using rat poison? by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Impact of the ICAL on the treatment of acute leukemia
22:42
22:42
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
22:42
Impact of the ICAL on the treatment of acute leukemia by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
Venetoclax: a primer by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Technological Solutions For Global Hematology And Oncology
17:09
17:09
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
17:09
Technological Solutions For Global Hematology And Oncology by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Lucky Iron Fish: a simple solution for iron deficiency
10:18
10:18
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
10:18
The Lucky Iron Fish: a simple solution for iron deficiency by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New developments in the management of sickle cell disease
12:29
12:29
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
12:29
New developments in the management of sickle cell disease by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Should we avoid heparin to eliminate HIT?
12:44
12:44
Daha Sonra Çal
Daha Sonra Çal
Listeler
Beğen
Beğenildi
12:44
Should we avoid heparin to eliminate HIT? by Blood Advances TalksBlood Advances Talks tarafından oluşturuldu
…
continue reading